Live Breaking News & Updates on Board Of Aion Therapeutic Inc
Stay updated with breaking news from Board of aion therapeutic inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate |Apollon Formularies Announcements | Apollon Formularies: Interim Results investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Apollon Formularies Plc (AQSE: APOL) ( Apollon or the Company ), a UK based international pharmaceutical company trading on the Aquis Stock Exchange is pleased to announce that its medical cannabis formulations were shown to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures in third party independent laboratory testing. ¹ This finding is in addition to the results recently announced on May 18, 2021² that Apollon formulations were successful in killing HER2+ breast cancer cells, and the announcement on June 28, 2021³ that Apollon formulations were successful in killing triple-negative breast cancer cells. This testing was performed under a joint testing agreement with Aion Therapeutic Inc. (CSE: AION) ( Aion ),a BC based international pharmaceutical company trading on the Canadian Securities Exchange. ....
Apollon Formularies (AQSE:APOL) | RNS | Apollon Formularies - Apollon Formulations Kill Prostate Cancer Cells proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Apollon Formulations Kill Triple-Negative Breast Cancer (TNBC) Cells Apollon Formularies plc (AQSE: APOL) ( Apollon or the Company ), a UK based international pharmaceutical company trading on Aquis Stock Exchange, is pleased to announce that its proprietary medical cannabis formulations were successful in killing triple-negative breast cancer (TNBC) cells in 3D cell cultures in third party independent laboratory testing. This finding is in addition to the results recently announced on May 18, 2021, that Apollon formulations were successful in killing HER2+ breast cancer cells. This testing was performed under a joint testing agreement with Aion Therapeutic Inc. (CSE: AION) ( Aion ), a BC based international pharmaceutical company trading on the Canadian Securities Exchange. ....